Hippocampal lesions are a defining pathology of Alzheimer's disease (AD). However, the molecular mechanisms that underlie hippocampal synaptic injury in AD have not been fully elucidated. Current therapeutic efforts for AD treatment are not effective in correcting hippocampal synaptic deficits. Growth hormone secretagogue receptor 1 (GHSR1) is critical for hippocampal synaptic physiology. Here, we report that GHSR1 interaction with -amyloid (A) suppresses GHSR1 activation, leading to compromised GHSR1 regulation of dopamine receptor D1 (DRD1) in the hippocampus from patients with AD. The simultaneous application of the selective GHSR1 agonist MK0677 with the selective DRD1 agonist SKF81297 rescued Ghsr1 function from A inhibition, mitigating hippocampal synaptic injury and improving spatial memory in an AD mouse model. Our data reveal a mechanism of hippocampal vulnerability in AD and suggest that a combined activation of GHSR1 and DRD1 may be a promising approach for treating AD.
INTRODUCTION
Hippocampal lesions are an early and defining pathology of Alzheimer's disease (AD) and underlie decline in cognitive ability (1) . Currently, no effective therapy exists to correct these hippocampal synaptic deficits (2) , and the precise mechanisms of hippocampal vulnerability in this neurodegenerative disorder are not completely understood. Growth hormone secretagogue receptor 1 (GHSR1), also known as ghrelin receptor, is a member of the class A G protein-coupled receptor (GPCR) family. Aside from its abundance in the pituitary gland and hypothalamus, GHSR1 is expressed in the hippocampus, both in the dentate gyrus and Ammon's horn (3) (4) (5) , indicating its relevance to hippocampal function. Several studies have demonstrated specific roles for hippocampal ghrelin/GHSR1 signaling in learning, motivational, and hedonic components of eating (6, 7) . Emerging evidence suggests a role for GHSR1 signaling in hippocampal synaptic physiology through regulation of dopamine receptor D1 (DRD1) (8) (9) (10) (11) (12) . The modulation of DRD1 signaling by GHSR1 is critical for initiating hippocampal synaptic reorganization via the noncanonical Gq-Ca 2+ signaling pathway that results in activation of Ca 2+ /calmodulindependent protein kinase II (CaMKII) (8, 9) . This pivotal role of GHSR1 in hippocampal synaptic function raises the question of whether GHSR1 dysfunction contributes to hippocampal synaptic deficits in AD.
Previous studies revealed inconsistent effects of GHSR1 activation on AD phenotypes in patients (10) and in AD animal and cell models (11) . Our own recent study in patients with mild cognitive impairment (MCI) showed a negative correlation between cognitive performance and circulating acylated ghrelin (12) . These results suggest that, in AD, hippocampal GHSR1 may become insensitive to activation by exogenous and endogenous ligands. Thus, understanding the functional status of hippocampal GHSR1 in AD-related conditions might provide insights into the molecular mechanisms of AD hippocampal pathology.
Here, we report increased GHSR1 expression and a direct interaction of GHSR1 with -amyloid (A) in the hippocampus of patients with AD and in a mouse model that mimics AD brain amyloidopathy with hippocampal synaptic injury (5×FAD mice). GHSR1 interaction with A inhibited its activation and prevented GHSR1/ DRD1 heterodimerization. Loss of Ghsr1 in mice replicated hippocampal synaptic stress and cognitive impairment seen in 5×FAD mice. Furthermore, our results showed that the combined activation of Ghsr1 and Drd1 with their selective agonists MK0677 and SKF81297, respectively, rescued hippocampal synaptic function and cognition in 5×FAD mice. (17) , on hippocampal tissues from four subjects with AD and four healthy donors. We observed A/GHSR1 complexes in hippocampi from patients with AD ( Fig. 1, A and B) . Moreover, 5×FAD mice at 4 and 9 months old exhibited increased hippocampal A/Ghsr1 complexes in an age-dependent manner (Fig. 1, C and D) . To validate the specificity of this interaction, we expressed full-length mouse Ghsr1 or its truncating mutants (figs. S2 and S3) in otherwise nonGhsr1-expressing human embryonic kidney (HEK) 293T cells, and the cells exhibited similar expression of FLAG-tagged Ghsr1 and its mutants ( Fig. 1G and fig. S4 ). HEK 293T cells expressing full-length mouse Ghsr1 or its mutants were exposed to 5 M oligomeric A42 for 24 hours followed by Duolink PLA to detect A/Ghsr1 complexes. In contrast to full-length Ghsr1 and other tested Ghsr1 mutants (Fig. 1 , E and F), Ghsr1 mutant devoid of amino acid (aa)42-116 (Ghsr1 aa42-116) showed no interaction with oligomeric A42 (Fig. 1, E and F) . The Duolink PLA results were further validated by using coimmunoprecipitation (Co-IP) (Fig. 1, H to J, and fig. S5 , A and B). These results confirm the interaction between the two proteins as seen in AD and further suggest that aa42-116 residues on Ghsr1 are critical for A binding. Together, our findings indicate that A physically interacts with GHSR1 in AD.
The interaction with A induces GHSR1 dysfunction
To determine whether A's interaction affects the function of Ghsr1, we examined Ghsr1 activity in A-enriched environments using fluorescein arsenical hairpin binder (FlAsH)-based fluorescence resonance energy transfer (FRET) assay, which is advantageous for GPCR activity assay because of its minimally perturbing effect on GPCR function (18) . FlAsH-based FRET was created by structural dynamics of Ghsr1 with FlAsH in the intercellular loop 3 and enhanced cyan fluorescent protein (ECFP) in the C terminus (Ghsr1 FIAsH/ECFP ).
Ghsr1
FIAsH/ECFP was expressed in HEK 293T cells, and changes in FRET ratio (F FIAsH /F ECFP ) were monitored for the measurement of agonist-induced Ghsr1 activation. No change in FRET ratio was detected in vehicle-treated Ghsr1
FIAsH/ECFP -expressing HEK 293T cells, whereas the administration of MK0677 (50 M) induced a decrease in FRET ratio (Fig. 2, A and B) . Ghsr1 antagonist JMV2959 (50 M) diminished MK0677-mediated FRET ratio change ( Fig. 2A) . These results indicate that agonist-induced Ghsr1 activation results in less energy transfer between ECFP and FlAsH ( fig. S6 ). Oligomeric A42 at indicated concentrations was applied on Ghsr1 FIAsH/ECFPexpressing HEK 293T cells for 5 min (preincubation) followed by coincubation with vehicle or Ghsr1 agonist MK0677. Although oligomeric A42 had no impact on FRET ratio in vehicle-treated cells, agonist-induced Ghsr1 activation was suppressed by oligomeric A42 (Fig. 2, A and B) , suggesting a Ghsr1 antagonist-like effect of oligomeric A42. Therefore, oligomeric A42 reduced the response of Ghsr1 to activation ( fig. S6 ) and that this effect was likely to be due, at least partially, to A/Ghsr1 interaction.
GHSR1 forms complex with DRD1 to regulate DRD1-mediated hippocampal synaptic strength and memory (8) . To fully evaluate the influence of A on GHSR1, we next examined whether oligomeric A42 affects the heterodimerization of GHSR1 and DRD1 by using HEK 293T cells coexpressing Ghsr1 and Drd1 (Fig. 2C and  fig. S2 ). After an incubation with oligomeric A42 (5 M) for 24 hours, the interaction between Ghsr1 and Drd1 determined by Duolink PLA was suppressed (Fig. 2, D and E) , indicating the inhibitory effect of oligomeric A42 on Ghsr1/Drd1 heterodimerization. To test whether GHSR1/DRD1 interaction was modulated in a clinical setting, we examined hippocampal tissues from five patients with AD and compared with tissues from five healthy controls. Analysis of Duolink PLA data showed a reduction of GHSR1/DRD1 complexes in hippocampi from subjects with AD compared with those from control subjects (Fig. 2, F and G), with a negative correlation between GHSR1/DRD1 complex density and the amounts of hippocampal soluble A40 and A42 ( fig. S7, A and B) . Decreased Ghsr1/Drd1 heterodimerization also occurred in 5×FAD mice, and this effect was exacerbated with age ( Fig. 2, H and I) . The preserved expression of DRD1 in hippocampi from subjects with AD ( fig. S8, A and B ) and 5×FAD mice ( fig. S8, C and D) suggests that decreased GHSR1/ DRD1 interaction in AD-relevant pathological settings is not due to DRD1 loss. FlAsH-based FRET assay was performed to examine the effect of oligomeric A42 (2 M, 5 min preincubation) on agonist (SKF81297, 100 M)-induced Drd1 activity in HEK 293T cells expressing Drd1 with FlAsH in the intercellular loop 3 and ECFP in the C terminus (Drd1 
Loss of Ghsr1 induces AD-like hippocampal synaptic stress and memory deficits
Because GHSR1 function is critical for hippocampal synaptic physiology (19), we hypothesized that Ghsr1-deficient mice would display AD-like synaptic loss in the hippocampus and cognitive impairment. To test this hypothesis, we measured synaptic density in hippocampal slices from Ghsr null (20) , nontransgenic (nonTg), 5×FAD, and Ghsr null/5×FAD mice at 4 and 9 months old. Ghsr null mice demonstrated reduced synapse density (Fig. 3, A and B) in the hippocampal CA1 region, one of the areas afflicted in AD with Ghsr1 abundance (5, 21) . The effect of the lack of Ghsr signaling on synaptic density is in agreement with a previous report (19) . We next examined longterm potentiation (LTP) in the hippocampal CA3-CA1 pathway (15) to determine the effect of Ghsr loss on synaptic strength. We found impairments of stimulus-evoked LTP on hippocampal slices from 9-month-old Ghsr null mice demonstrated by decreased field excitatory postsynaptic potential (fEPSP) slope after theta burst stimuli at 40 to 60 min (Fig. 3C ) without altering baseline input-output relationships of the evoked responses ( fig. S10 ). Moreover, loss of Ghsr impaired hippocampus-dependent spatial navigation in the Morris water maze test (Fig. 3, D , E, G, and H) without affecting mouse swimming speed (Fig. 3, F and I ). These changes in Ghsr null mice were in line with phenotypic alterations observed in age-and gendermatched 5×FAD mice (Fig. 3, D to I) . Ghsr null/5×FAD showed no major differences in the tested parameters relative to their age-and gender-matched 5×FAD littermates (Fig. 3 , A to I) and no differences in hippocampal A loading ( fig. S11 ) or serum ghrelin ( fig. S12 ). These results suggest that the impairments observed in Ghsr null and in 5×FAD mice might be mediated by overlapping mechanisms. The regulation of DRD1 by GHSR1 is pivotal for hippocampal synaptic plasticity, which is modulated through the activation of CaMKII downstream of DRD1 signaling (8) . To determine whether impaired CaMKII activation due to Ghsr1 deregulation is involved in hippocampal 3 of 14 synaptic deficits in 5×FAD mice, we examined CaMKII phosphorylation at Thr 286 (P-CaMKII Thr
286
), an activated form of CaMKII (22) , in postsynaptic densities isolated from mouse hippocampus by immunoblotting to reflect CaMKII activation at hippocampal postsynapses. Decreased CaMKII phosphorylation at Thr 286 was detected in hippocampal postsynaptic densities from 9-month-old Ghsr null, 5×FAD, and Ghsr null/5×FAD mice as compared with their nonTg littermates ( fig. S13 ). Ghsr1 deficiency did not affect the expression . These results implicate the detrimental effect of Ghsr1 deregulation on Drd1-related CaMKII signaling in 5×FAD mice. Together, our findings support the idea that A-induced Ghsr1 deregulation underpins hippocampal synaptic deficits and cognitive decline in 5×FAD mice.
Reduced Ghsr1/Drd1 interaction contributes to A-induced hippocampal synaptic injury
Given the deleterious influence of the GHSR1 deficiency on hippocampal synapses, we asked whether GHSR1 activation could restore synaptic function in A-rich environments. To directly test this, we applied the Ghsr1 agonist MK0677 to oligomeric A42-exposed (H) Analysis of Ghsr1/Drd1 PLA-positive dots in hippocampal CA1 region in 4-and 9-month-old 5×FAD mice. *P < 0.05 and **P < 0.01, unpaired Student's t test. n = 3 for each group. (I) Representative 3D reconstructed images of Ghsr1/Drd1 PLA-positive dots in the hippocampus of 4-and 9-month-old nonTg and 5×FAD mice. Ghsr null mice at 9 months old were used as critical negative control.
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Fig. 3. Loss of Ghsr replicates AD-like phenotypes.
(A) Analysis of synaptic density in CA1 regions from 4-and 9-month-old mice. **P < 0.001 and ***P < 0.001 nonTg versus other groups at the same age, one-way ANOVA followed by Bonferroni post hoc analysis. Four-month-old mice: nonTg, n = 4; 5×FAD, n = 7; Ghsr null mice, n = 5; and Ghsr null/5×FAD, n = 4. Nine-month-old mice: nonTg, n = 4, 5×FAD, n = 4, Ghsr null mice, n = 4, and Ghsr null/5×FAD, n = 3. (B) Representative 3D reconstructed images of synapse staining. Vesicular glutamate transporter 1 (vGLUT1, blue) and postsynaptic density 95 (PSD95, red) were used to visualize pre-and postsynaptic terminals, respectively. The overlapped staining of vGLUT1 and PSD95 indicates synapses. (C) Time course of LTP and representative fEPSP responses during the baseline period (black trace) and 30 s after theta burst simulation (red trace) in four groups of mice at 9 months old. *P < 0.05 and ***P < 0.001 nonTg versus other groups, one-way ANOVA followed by Bonferroni post hoc analysis. nonTg, n = 5; 5×FAD, n = 4; Ghsr null, n = 5; and Ghsr null/5×FAD, n = 5. (D to I) Spatial navigation of four groups of mice in the Morris water maze test. (D and G) Spatial learning of four groups of mice at 4 (D) and 9 (G) months old. *P < 0.05, **P < 0.01, and ***P < 0.001, nonTg versus other groups on the same day, one-way ANOVA followed by Bonferroni post hoc analysis. (E and H) Spatial reference memory of different groups of mice at 4 (E) and 9 (H) months of age. *P < 0.05, one-way ANOVA followed by Bonferroni post hoc analysis. (F and I) Swimming speed of four groups of mice at 4 (F) and 9 (I) months old. Four-month-old mice: nonTg, n = 7; 5×FAD, n = 9; Ghsr null mice, n = 10; and Ghsr null/5×FAD, n = 6. Nine-month-old mice: nonTg, n = 8; 5×FAD, n = 11; Ghsr null mice, n = 5; and Ghsr null/5×FAD, n = 8.
hippocampal neuron cultures. Our interest in MK0677 derives from the translational potential of MK0677, a nonpeptide ghrelin mimetic compound with higher potency than ghrelin (23) . The agonist MK0677 alone at doses greater than 1.5 M substantially promoted synaptic formation demonstrated by increased synaptic density ( fig. S14A ), suggesting that Ghsr1 activity can induce synaptogenesis. However, administration of MK0677 (1.5 M) did not mitigate oligomeric A42 (1 M, 24 hours)-induced synapse loss in hippocampal neuron cultures (Fig. 4, A and B) , which is consistent with our finding that oligomeric A42 blunts MK0677-mediated Ghsr1 activation. Because MK0677 alone was not protective against oligomeric A42-induced synapse loss, we further explored the importance of Ghsr1/Drd1 interaction. We sought to promote Ghsr1 regulation of Drd1 by increasing Ghsr1/Drd1 heterodimerization through simultaneously activating Ghsr1 and Drd1 in cultured mouse hippocampal neurons. The optimal dose for the selective Drd1 agonist SKF81297 (2 M) was determined on the basis of its capability in promoting synapse formation in cultured mouse hippocampal neurons ( fig. S14B ). Same as MK0677, SKF81297 itself increased synaptic density in cultured mouse hippocampal neurons but failed to alleviate oligomeric A42 (1 M, 24 hours)-induced synapse loss in hippocampal neuron cultures (Fig. 4, A and B) . In contrast to MK0677 or SKF81297 alone, the simultaneous stimulation of Ghsr1 and Drd1 using both compounds (1.5 M MK0677 and 2 M SKF81297) increased synaptic density in oligomeric A42 (1 M, 24 hours)-treated mouse hippocampal neuron cultures (Fig. 4, A and B) . Consistent with this observation, coapplication of MK0677 and SKF81297, but not the agonists alone, preserved Ghsr1/Drd1 complex formation from oligomeric A42 (1 M, 24 hours) (Fig. 4, C and D) . These results indicate that interaction of Ghsr1/Drd1 promotes synaptic formation in hippocampal neurons, which is in agreement with previous reports (8), and they further support the hypothesis that perturbed GHSR1 regulation of DRD1 contributes to synaptic injury in AD.
To verify this hypothesis in A overexpression-mediated model of synaptic injury, we applied MK0677 (1.5 M) and SKF81297 (2 M), alone or in combination, to hippocampal slices from 4-month-old nonTg and 5×FAD mice and examined LTP to reflect synaptic strength in the hippocampal CA3-CA1 pathway. Previous studies (13) showed that 5×FAD mice present early hippocampal synaptic lesions at 4 months of age. Vehicle-treated 5×FAD hippocampal slices exhibited impairments of stimulus-evoked LTP (Fig. 4E) , indicating decreased synaptic strength. The treatment of MK0677 or SKF81297 alone had no effect on hippocampal LTP in 5×FAD hippocampal slices (Fig. 4E ). In contrast, simultaneous application of MK0677 and SKF81297 markedly mitigated impairments of stimulus-evoked LTP in 5×FAD hippocampal slices (Fig. 4E) . The treatment of MK0677 or SKF81297 alone or in combination had no effect on hippocampal LTP in brain slices from nonTg mice ( fig. S15 ). In view of damaged excitatory synaptic transmission in AD (24), we next examined the effect of the MK0677/ SKF81297 mixture on excitatory synaptic transmission in the hippocampus of 5×FAD mice at 4 months old by performing whole-cell recordings of miniature excitatory postsynaptic currents (mEPSCs). Although no genotypic effect on mEPSC frequency was observed (Fig. 4, F and H) , CA1 neurons from 5×FAD mice demonstrated a decrease in mEPSC amplitude, which was protected by the MK0677/ SKF81297 mixture (Fig. 4, G and H) . Because mEPSC frequency primarily represents the probability of presynaptic release and mEPSC amplitude is largely associated with the conductance of postsynaptic receptors (25), the results suggest improved postsynaptic receptor function in MK0677/SKF81297-treated 5×FAD CA1 neurons. Together, these findings strongly suggest a role for dysfunctional GHSR1 regulation of DRD1 in AD hippocampal synaptic failure and also indicate that combined stimulation of GHSR1 and DRD1 can rescue A-induced hippocampal synaptic deficits.
Ghsr1/Drd1 coactivation rescues Ghsr1 function from A toxicity
To assess whether the protective effects of Ghsr1 and Drd1 coactivation were mediated by Ghsr1 activity, we measured Ghsr1 activity by FlAsH-based FRET on HEK 293T cells either expressing Ghsr1
FIAsH/ECFP alone or coexpressed with Drd1. The cells were exposed to vehicle treatment or the mixture of MK0677 (50 M) and SKF81297 (100 M) in the presence or absence of a 5-min pretreatment of 2 M oligomeric A42. Without oligomeric A42, the two types of cells exhibited similar response to the combined treatment (Fig. 5A ), indicating that Ghsr1 was activated by its agonist regardless of Drd1 expression. The inhibitory effect of oligomeric A42 on Ghsr1 activation was diminished in MK0677/SKF81297 mixturetreated Ghsr1/Drd1 coexpressing cells (Fig. 5A) . These results suggest that coactivation of Ghsr1 and Drd1 can prevent A-induced effects on Ghsr1. In further support of this hypothesis, the MK0677/ SKF81297 mixture, but not MK0677 or SKF81297 alone, alleviated A/Ghsr1 complex formation in oligomeric A42 (1 M, 24 hours)-treated mouse hippocampal neuron cultures (Fig. 5, B and C) . Together, these results suggest that Ghsr1/Drd1 coactivation preserves Ghsr1 activity by reducing the interaction between A and Ghsr1.
Ghsr1/Drd1 coactivation rescues synaptic density and memory in 5×FAD mice Next, we attempted to replicate our findings in vivo. Because 5×FAD mice begin to exhibit compromised spatial learning and memory at 4 to 5 months old (26-28), we expected that Ghsr1/Drd1 coactivation would restore hippocampal synaptic function and improve behavior in young 5×FAD mice at 4 to 5 months old when hippocampal lesions are limited and A accumulation is low (26) (27) (28) . Age-and gendermatched nonTg and presymptomatic 5×FAD mice ("presymptomatic" refers to unaffected spatial learning and memory) at 3 months old received daily intraperitoneal injections of the MK0677/SKF81297 combination therapy [MK0677 (1 mg/kg) and SKF81297 (1.5 mg/kg)] for 30 days followed by behavioral experiments at 4 months of age. These treatment regimens were optimized on the basis of preliminary experiments that took into account the influence on body weight ( fig. S16, A and C), serum ghrelin (fig. S16, B and D) , and behavioral performance (Fig. 6, A to C, and fig.S16 , E to G), as well as previous reports (29, 30) . Saline-treated 5×FAD mice demonstrated memory defects in the Morris water maze test, which were prevented by treatment with MK0677/SKF81297 (Fig. 6, A to C) . Moreover, mice that received MK0677/SKF81297 treatment maintained body weight ( fig. S16A ) and serum ghrelin amount ( fig. S16B ) and showed unaffected cell density in the liver, kidney, and brain ( fig. S17 ). 5×FAD mice treated with MK0677/SKF81297 showed considerably less hippocampal CA1 synapse loss (Fig. 6, D and E) , preserved Ghsr1/Drd1 heterodimerization (Fig. 6, F and G) , and fewer A/Ghsr1 complexes (Fig. 6, H and I ) as compared with their vehicle-treated counterparts. In addition, because Ghsr1 activation has been shown to improve hippocampal neurogenesis in 5×FAD mice (31), we examined neurogenesis in the dentate gyrus by performing immunocytochemistry staining of adult brain 7 of 14 neurogenesis marker, doublecortin (DCX) (32) . Compared with their vehicle-treated counterparts, MK0677/SKF81297-treated 5×FAD mice exhibited increased DCX-positive neurons in their dentate gyrus ( fig. S18 ).
Ghsr1/Drd1 coactivation does not affect hippocampal amyloidosis or tau pathology in 5×FAD mice
To determine whether synaptic function and memory improvement in MK0677/SKF81297-treated 5×FAD mice were associated with on synaptic density in hippocampal neurons in the presence or absence of oligomeric A42 (1 M, 24 hours). ***P < 0.001 vehicle-treated versus oligomeric A42-treated groups, two-way ANOVA followed by Bonferroni post hoc analysis. Data were collected from three independent experiments. n = 30 to 48 neurites. (B) Representative 3D reconstructed images of synapse staining. vGLUT1 (blue) and PSD95 (red) were used to visualize pre-and postsynaptic terminals, respectively. The dendrites were stained with MAP2 (green). The overlaid staining of vGLUT1/PSD95 identifies synapses. (C) Effect of different treatments (1.5 M MK0677, 2 M SKF81297, or in combination) on Ghsr1/Drd1 complex in hippocampal neurons in the presence or absence of oligomeric A42 (1 M, 24 hours). **P < 0.01 and ***P < 0.001 vehicle-treated versus oligomeric A42-treated groups, two-way ANOVA followed by Bonferroni post hoc analysis. Data were collected from three independent experiments. n = 8 to 10 neurons. (D) Representative images of Ghsr1/Drd1 PLA-positive dots. (E) Time course of LTP and representative fEPSP responses during the baseline period (black trace) and 30 s after theta burst simulation (red trace) in five treatment groups at 4 months of age. **P < 0.01 5×FAD MK0677/SKF81297 versus 5×FAD saline, one-way ANOVA followed by Bonferroni post hoc analysis. nonTg saline, n = 9; 5×FAD saline, n = 10; 5×FAD MK0677/SKF81297, n = 7; 5×FAD MK0677, n = 9; and 5×FAD SKF81297, n = 9. (F to H) mEPSC frequency (F) and amplitude (G) in the indicated groups of 4-month-old mice. *P < 0.05 and **P < 0.01, one-way ANOVA followed by Bonferroni post hoc analysis. n = 6. (H) Representative traces of mEPSC recordings. altered A production and deposition, we examined hippocampal tissues from MK0677/SKF81297-and vehicle-treated 5×FAD mice. Immunoblotting assay using antibody against amyloid precursor protein (APP) was performed to examine APP expression in hippocampal homogenates (Fig. 7A) . Immunohistochemical staining using antibody against A was performed to detect A load on hippocampal slices (Fig. 7B) . The amounts of soluble A40 and A42 in hippocampal homogenates were measured by enzyme-linked immunosorbent assay (Fig. 7C) . Moreover, because 5×FAD mice have intraneuronal A deposition in addition to extracellular A plaques mimicking AD brain amyloidosis (13), we further examined intraneuronal A deposition in hippocampal CA1 neurons demonstrated by the overlapping staining of A and class III -tubulin, a specific neuronal marker (Fig. 7D) (33) , as well as extracellular amyloid plaques in the hippocampus determined by Congo red-positive staining (Fig. 7E) . No difference in these parameters was observed between MK0677/ SKF81297-and vehicle-treated 5×FAD mice (Fig. 7, A to E) . In addition, to determine whether MK0677/SKF81297 treatment affects tau pathology, we analyzed tau phosphorylation by performing immunoblotting on mice hippocampal homogenates. Tau phosphorylation at multiple phosphorylation sites including Ser or total tau in 5×FAD mice were not changed by MK0677/SKF81297 treatment (Fig. 7F) . Therefore, the protective effects of MK0677/ SKF81297 treatment do not result from modulation on brain amyloidosis or tau pathology.
DISCUSSION
Recent studies highlighted the importance of GHSR1 in hippocampal synaptic physiology (8, 19, 34) , but the functional status of GHSR1 in AD remains largely unknown. In this study, we found elevated expression of GHSR1 in the hippocampus from patients with AD and in 5×FAD mice. Our recent observation of an inverse relationship between serum acylated ghrelin amounts and cognitive function in MCI (12) , as well as our findings here showing that A alters the response of Ghsr1 to its agonist and that a strong correlation of GHSR1 expression with soluble A amounts in subjects with AD exists, seem to suggest that increased GHSR1 expression in hippocampi from patients with AD might reflect a compensatory response to A toxicity. Our results are in disagreement with a previous report showing decreased GHSR1 mRNA in temporal gyri from patients with AD (35) . This difference may result from different mechanisms of regulation of GHSR1 at the pre-and posttranscriptional steps and/or a brain region-specific response to A toxicity. Because GHSR1 expression is relatively low in the neocortex (5), it is unclear whether the decreased GHSR1 mRNA expression in the neocortical temporal lobe contributes to AD. Furthermore, it should be noted that GHSR1, a truncated splice variant of GHSR1, blocks GHSR1 function (36) , and the aforementioned study reported increased GHSR1 mRNA in neocortical temporal tissues from subjects with AD (35) . Therefore, GHSR1 may also contribute to hippocampal GHSR1 deregulation in AD. Additional studies are needed to address these questions and to understand the contribution of the GHSR/ghrelin system in AD pathogenesis. Here, we show that hippocampal GHSR1 deregulation can be induced through a physical interaction with A, and we established a link between Ghsr1 deregulation, hippocampal synaptic injury, and cognitive impairments in mice. The alterations in Ghsr1 in young 5×FAD mice and the abnormal increase of acylated ghrelin in patients with MCI (12) seem to suggest that GHSR1 deregulation may develop in prodromal or early stages of the disease. Studies of postmortem tissues from preclinical patients with AD could help to address this possibility.
Substantial efforts are currently directed toward the development of new AD treatments, especially toward the development of diseasemodifying therapies (37) . However, current AD interventions, including acetylcholinesterase inhibitors or N-methyl-d-aspartate receptor blockers, do not target the underlying mechanisms that cause synaptic injury and thus have limited efficacy (2, 38, 39) . Moreover, ongoing attempts to remove A or ameliorate tau pathology have yet to 
-min pretreatment). Cells expressing Ghsr1
FIAsH/ECFP alone or coexpressed with Drd1 were used.
Data were collected from a microplate reader. ***P < 0.001, two-way ANOVA followed by Bonferroni post hoc analysis. Data were collected from three independent experiments. n = 9 to 25 samples. (B and C) Effect of different treatments (1.5 M MK0677, 2 M SKF81297, or in combination) on A/Ghsr1 complex in oligomeric A42 (1 M, 24 hours)-treated hippocampal neurons. *P < 0.05, one-way ANOVA followed by Bonferroni post hoc analysis. Data were collected from three independent experiments. n = 10 neurons per group.
9 of 14 Spatial learning. **P < 0.01 and ***P < 0.001 5×FAD saline versus other groups, two-way ANOVA followed by Bonferroni post hoc analysis. (B) Spatial reference memory. ***P < 0.001 5×FAD saline versus other groups, two-way ANOVA followed by Bonferroni post hoc analysis. (C) Swimming speed. nonTg saline, n = 8; 5×FAD saline, n = 8; nonTg MK0677/SKF81297, n = 7; and 5×FAD MK0677/SKF81297, n = 5. (D and E) Analysis of synaptic density in the hippocampal CA1 region. **P < 0.01 and ***P < 0.001 5×FAD saline versus other groups, two-way ANOVA followed by Bonferroni post hoc analysis. nonTg saline, n = 3; 5×FAD saline, n = 4; nonTg MK0677/SKF81297, n = 4; and 5×FAD MK0677/SKF81297, n = 4. (E) Representative 3D reconstructed images of synapse staining in the CA1 region. vGLUT1 (blue) and PSD95 (red) were used to visualize pre-and postsynaptic components, respectively. The overlaid staining of vGLUT1 and PSD95 indicates synapses. (F and G) Analysis of Ghsr1/Drd1 complex in the CA1 region. ***P < 0.001 5×FAD saline versus other groups, two-way ANOVA followed by Bonferroni post hoc analysis. n = 4 per group. (G) Representative 3D reconstructed images of Ghsr1/Drd1 PLA-positive dots (red). Nuclei were stained with DAPI. (H and I) Analysis of A/Ghsr1 PLA-positive dots in CA1 region. ***P < 0.001, unpaired Student's t test. n = 4 per group. (I) Representative 3D reconstructed images of A/Ghsr1 PLA dots (red). Nuclei were stained with DAPI.
prove effective (40, 41) . Our results identify GHSR1, and particularly its interaction with DRD1, as a target for AD treatment with translational potential. Studies that previously explored GHSR1 agonism for the treatment of AD produced inconsistent results (10, 11) . GHSR1 agonists such as MK0677 and LY444711 provided protection in animal and cell models (42) (43) (44) (45) ; however, a clinical trial of MK0677 in patients with AD failed to show clinical benefits (10) . Although this trial was originally designed to enhance brain A clearance by augmenting insulin-like growth factor 1 release (10), its negative outcome discouraged further attempts to target GHSR1 in AD. We speculate here that a potential explanation for this clinical trial's failure may be that GHSR1 becomes insensitive to its agonists in AD. Previous studies found ghrelin (44) or acylated ghrelin (46) is protective against acute A-induced synaptic dysfunction, cognitive impairments, and neuroinflammation. Discrepancies between these studies and ours may reflect differences in the degree of A exposure, as A overexpression in transgenic mouse models of AD exerts a more insidious and sustained deleterious effect than transient A exposure (47). In contrast to our observation of no effect of the treatment on hippocampal A load in 5×FAD mice, a recent study did report that MK0677 treatment lowered neocortical A plaques in young 5×FAD mice (43) . A higher dose of MK0677 used in that study in comparison to ours may partially explain this discrepancy in the effect of Ghsr1 activation on A load. In addition, a previous study from this group found that systemic ghrelin treatment did not affect hippocampal A load in 5×FAD mice (31) . We cannot rule out that MK0677 may affect A production and/or clearance in a dose-dependent manner. This idea requires further investigation, taking into account the potential systemic effects on body weight and glucose regulation of high doses of this drug because obesity is a risk factor for AD (48) . GHSR1 and DRD1 are abundantly coexpressed in the hippocampus and are believed to serve important roles in hippocampal function (19, 49) . Kern and colleagues have determined a mechanism that links GHSR1 and DRD1 in the regulation of hippocampal synaptic function. They found that activated GHSR1 shifts DRD1 from a Gs to a Gq state via the formation of GHSR1/DRD1 heterodimers, which allows dopamine to activate hippocampal synaptic activity-related Ca 2+ signaling (8) . This pivotal role of the GHSR1/ DRD1 heterodimer in hippocampal synaptic physiology reinforces considering coactivation of GHSR1 and DRD1 for restoring synaptic defects. A further relevant finding from our study is that coactivation of Ghsr1/Drd1 protects Ghsr1 from A toxicity. We propose that this resistance to A is conferred through a Ghsr1 conformational change that arises via its interaction with Drd1. This observation provides another potential explanation for why using a GHSR1 agonist in isolation lacked clinical efficacy. In support of this hypothesis, previous studies revealed that simultaneous use of agonists of different GPCR family members can induce allosteric interactions and alterations in functional properties (50, 51) . Moreover, although we did not observe DRD1 alterations in AD hippocampi, we cannot conclude that DRD1 function is intact in AD. In addition to the observation that DRD1 B2 allele is an AD risk factor (52) , previous studies showed damage in the locus coeruleus in patients with AD (53) . Because tyrosine hydroxylase-expressing neurons in the locus coeruleus project to the hippocampus, which enhances synaptic activity and hippocampus-related memory via D1-type dopamine receptors (54), it is therefore possible that dopaminergic input to the hippocampus is altered in AD. In this regard, the impaired regulation of DRD1 by GHSR1 in AD-related conditions may also result from insufficient supply of dopamine, DRD1's natural ligand, in the hippocampus, which could be mitigated by the supplementation of DRD1 agonist. Last, in this study, we used young 5×FAD mice, which have relatively mild synaptic lesions and no hippocampal neuron loss (13) . Whether MK0677/SKF81297 benefits older 5×FAD mice with more pervasive hippocampal lesions remains untested and need further investigation. Nevertheless, this proof-of-concept study shows the potential protective effects of this AD dual GPCR agonist intervention. MK0677 is approved by Food and Drug Administration, and although SKF81297 is not, other DRD1 agonists including levodopa and pergolide are clinically available for clinical use (55) .
Another question related to the protective effects of the treatment merits discussion is the role of neurogenesis. A previous study suggested that ghrelin attenuates hippocampal pathology in 5×FAD mice by potentiating hippocampal neurogenesis (31) . Similarly, in our study, we found that coactivation of Ghsr1 and Drd1 promotes neurogenesis in the dentate gyrus of mixture-treated 5×FAD mice. The neurogenic effect of GHSR1 has been linked to its role in hippocampal energy metabolism (56) . However, the impact of altered neurogenesis on cognitive impairments in AD and whether neurogenesis can correct synaptic and brain network injury remained unclear (57) .
Previous studies directly attributed hippocampal synaptic injury that was observed in AD to A toxicity and/or tauopathy (58). Although our current study explored Ghsr1 defects in the context of an A-rich environment, potential broader effects of Ghsr1 deregulation on hippocampal metabolic processes and calcium signaling should not be overlooked. It is well documented that alterations in metabolic hormones such as ghrelin, leptin, and insulin can affect feeding behavior and nutrient availability, culminating in alterations of brain energy homeostasis and synapse remodeling (19, 59) . Therefore, ghrelin system perturbations could cause brain and systemic metabolic deregulation, which is strongly associated with deficits in synaptic activity and hippocampus-dependent memory in both aging and AD (19) . Moreover, the hypothalamus, a target of many metabolic hormones, plays a crucial role in maintaining brain metabolic homeostasis and hippocampal synaptic physiology (60) . Hypothalamic pathology occurs in patients with AD (61). Therefore, given GHSR1's role in hypothalamic function (62) , it is possible that GHSR1 deregulation may affect hypothalamic function and indirectly drive hippocampal damage. We cannot rule out the possibility that the treatment-derived neuroprotection in our study may, at least in part, reflect improvements in hippocampal energy metabolism that arises secondary to effects on hypothalamic GHSR1. Moreover, in view of the influence of GHSR1 on DRD1-mediated Ca 2+ signaling pathway related to hippocampal synaptic plasticity (8) , GHSR1 deregulation may also represent a mechanism of calcium signaling-associated selective neuronal vulnerability of AD hippocampi (63) . In this context, altered hypothalamic-hippocampal connectivity and perturbed calcium signaling at synapses that result from GHSR1 dysfunction might act as critical A-independent metabolic and calcium-related mechanisms of hippocampal synaptic failure in AD.
In summary, we have demonstrated a mechanism of hippocampal pathology through GHSR1 deregulation and showed that restoring Ghsr1/Drd1 activity prevented AD-mediated synaptic abnormalities and behavioral impairments in a mouse model of AD. The most parsimonious interpretation of our findings is that GHSR1 deregulation mediates hippocampal damage and that targeting this pathological mechanism might therefore prove therapeutically useful.
MATERIALS AND METHODS
Study design
The objective of this study was to determine the role of GHSR1 in AD pathology and develop a strategy for preventing AD phenotype in a mouse model. Hippocampal tissues from patients with AD and nonAD controls were analyzed to determine GHSR1 expression, A/GHSR1 interaction, and GHSR1/DRD1 complexes. The transgenic 5×FAD mouse model was used to mimic AD amyloidopathy (27) . Ghsr null (20) and Ghsr null/5×FAD mice were used to explore the role of GHSR1 deficiency in an AD-like environment. To mimic MCI and later stage AD, respectively, the studies were performed using 4-and 9-month-old mice. Both male and female mice were used. The investigators performing the experiments did not allocate the mice.
For all the experiments, sample sizes were determined by our previous data, prior literature, and power calculation to ensure sufficient sample sizes to allow the detection of statistically significant differences. Sample exclusion was not permitted. The number of unique replicates for each experiment is specified in the figure legends. Mice were randomized by genotype and gender during behavioral testing. For the behavioral, electrophysiological, pathological, and Duolink PLAs, experimenters were blinded during data acquisition and unblinded for data analysis. Raw data are provided in table S2 (separate Excel file).
Statistical analysis
Statistical comparisons were performed using GraphPad Prism 5 software. One-way or two-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis or unpaired two-way Student's t test were applied in data analysis. Pearson's correlation coefficient was used for correlation testing. Numbers of replicates and P values are stated in each figure legend. All data were expressed as means ± SEM except for the box plots, which were shown as maximum, median, and minimum. Significance was concluded when the P value was less than 0.05. Significance was indicated by *P < 0.05, **P < 0.010, ***P < 0.001, #P < 0.001, and †P < 0.001. NS (not significant) denotes P > 0.05.
SUPPLEMENTARY MATERIALS
stm.sciencemag.org/cgi/content/full/11/505/eaav6278/DC1 Materials and Methods Fig. S1 . Expression of GHSR1 increased in hippocampi from subjects with AD and 9-month-old 5×FAD mice. Fig. S2 . Expressions of Ghsr1 and Drd1 were validated in transfected HEK 293T cells. Fig. S3 . Schematic diagram shows the sequence of full-length Ghsr1 and its truncating mutants. Fig. S4 . FLAG-tagged Ghsr1 and its truncating mutants were similarly expressed in HEK 293T cells. Fig. S5 . The interaction between Ghsr1 mutants and A42 was assessed by using Co-IP. Fig. S6 . Schematic diagram represents FlAsH-FRET assay for Ghsr1 activity and the impact of oligomeric A42 on Ghsr1 activation. Fig. S7 . GHSR1/DRD1 complex density was negatively correlated with hippocampal soluble A40 or A42 amounts in subjects with AD. Fig. S8 . Expression of hippocampal DRD1 remained unaltered in hippocampi from subjects with AD and 5×FAD mice. Fig. S9 . Oligomeric A42 did not affect agonist-induced activation of Drd1 or form complex with Drd1. Fig. S10 . Input/output curves of fEPSPs were similar in four types of transgenic mice. Fig. S11 . A deposition in the hippocampus remained unchanged in Ghsr null/5×FAD mice as compared with their 5×FAD littermates. Fig. S12 . Serum ghrelin amounts were similar in four types of transgenic mice. Fig. S13 . Loss of Ghsr1 suppressed postsynaptic CaMKII activation in the hippocampus. Fig. S14 . The optimal doses of MK0677 and SKF81297 were determined by their augmenting effect on synaptogenesis in cultured hippocampal neurons. Fig. S15 . Time course of LTP and fEPSP amplitudes was not changed by different treatments on hippocampal slices from nonTg mice. Fig. S16 . The doses of MK0677/SKF81297 treatment were optimized on the basis of the influence on body weight, serum ghrelin, and behavioral performance. Fig. S17 . MK0677/SKF81297 [MK0677 (1 mg/kg) and SKF81297 (1.5 mg/kg)] treatment on mice had no effect on hepatic, renal, and hippocampal cell density. Fig. S18 . MK0677/SKF81297 [MK0677 (1 mg/kg) and SKF81297 (1.5 mg/kg)] treatment improved neurogenesis in the dentate gyrus of 5×FAD mice. Table S1 . Human brain tissue information. Table S2 . Raw data (provided as separate Excel file). References (64) (65) (66) (67) (68) (69) (70) (71) (72) 
